FDA approves Medtronic's new pacemaker system:
This article was originally published in Clinica
The Medtronic Kappa 700 implantable pacing series has received premarket approval from the US FDA. The Minneapolis, Minnesota-based company says its new series of pacemaker systems is able to detect and respond to atrial arrhythmias with appropriate pacing within seconds. Other features of the series include the Remote Assistant, a hand-held monitor which allows patients to check the status of their pacing leads and pacemakers, and Medtronic.Vision software which provides doctors with patient demographics, test results and diagnostic data.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.